Tissue Transglutaminase (TG2)-induced inflammation in initiation, progression, and pathogenesis of pancreatic cancer

Cancers

Volumn 3, Issue 1, 2011, Pages 897-912

  Mehta, Kapil ^a,b   Han, Amy ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer stem cell; Chemoresistance; Epithelial to mesenchymal transition; Inflammation; Metastasis

Indexed keywords

ANTIINFLAMMATORY AGENT; DOXORUBICIN; GEMCITABINE; LIPOSOME; NANOCARRIER; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SMALL INTERFERING RNA; TISSUE TRANSGLUTAMINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC PANCREATITIS; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GENETIC DISORDER; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRECANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 79953674804     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010897     Document Type: Review

References (69)

1. Warshaw, A.L.; Fernadez-del Castillo, C. Pancreatic carcinoma. New Eng. J. Med. 1992, 326, 455-465.
2. Whitcomb, D.C.; Applebaum, S.; Martin, S.P. Hereditary pancreatitis and pancreatic carcinoma. Ann. NY Acad. Sci. 1999, 880, 201-209.
3. Talamini, G.; Bassi, C.; Falconi, M.; Sartori, N.; Salvia, R.; Rigo, L.; Castagnini, A.; Di Francesco, V.; Frulloni, L.; Bovo, P.; Vaona, B.; Angelini, G.; Vantini, I.; Cavallini, G.; Pederzoli, P. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Digest. Dis. Sci. 1999, 44, 1303-1311.
4. Rozenblum, E.; Schutte, M.; Goggins, M.; Hahn, S.A.; Panzer, S.; Zahurak, M.; Goodman, S.N.; Sohn, T.A.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997, 57, 1731-1734.
5. Hruban, R.H.; Mansfeld, A.D.; Offerhaus, G.J.; van Weering, D.H.; Allison, D.C.; Goodman, S.N.; Kensler, T.W.; Bose, K.K.; Cameron, J.L.; Bos, J.L. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 1993, 143, 545-554.
6. Hruban, R.H.; Wilentz, R.E.; Kern, S.E. Genetic progression in the pancreatic ducts. Am. J. Pathol. 2000, 156, 1821-1825.
7. Poulsen, H.E.; Prieme, H.; Loft, S. Role of oxidative DNA damage in cancer initiation and promotion. Eur. J. Cancer Prev. 1998, 7, 9-16.
8. Wiseman, H.; Halliwell, B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem. J. 1996, 313, 17-29.
9. Masamune, A.; Shimosegawa, T. Signal transduction in pancreatic stellate cells. J. Gastroenterol. 2009, 44, 249-260.
10. Cheung, W.; Darfler, M.M.; Alvarez, H.; Hood, B.L.; Conrads, T.P.; Habbe, N.; Krizman, D.B.; Mollenhauer, J.; Feldmann, G.; Maitra, A. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008, 8, 608-616.
11. Verma, A.; Wang, H.; Manavathi, B.; Fok, J.Y.; Mann, A.P.; Kumar, R.; Mehta, K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006, 66, 10525-10533.
12. Iacobuzio-Donahue, C.A.; Ashfaq, R.; Maitra, A.; Adsay, N.V.; Shen-Ong, G.L.; Berg, K.; Hollingsworth, M.A.; Cameron, J.L.; Yeo, C.J.; Kern, S.E.; Goggins, M.; Hruban, R.H. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63, 8614-8622.
13. Priglinger, S.G.; May, C.A.; Neubauer, A.S.; Alge, C.S.; Schönfeld, C.L.; Kampik, A.; Welge-Lussen, U. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes. Invest. Ophthalmol. Vis. Sci. 2003, 44, 355-364.
14. Lee, K.N.; Birckbichler, P.J.; Patterson, M.K., Jr. GTP hydrolysis by guinea pig liver transglutaminase. Biochem. Biophys. Res. Commun. 1989, 162, 1370-1375.
15. Iismaa, S.E.; Mearns, B.M.; Lorand, L.; Graham, R.M. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol. Rev. 2009, 89, 991-1023.
16. Mehta, K.; Kumar, A.; Kim, H.I. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem. Pharmacol. 2010, 80, 1921-1929.
17. Piacentini, M.; Rodolfo, C.; Farrace, M.G.; Autuori, F. "Tissue" transglutaminase in animal development. Int. J. Dev. Biol. 2000, 44, 655-662.
18. Csomós, K.; Német, I.; Fésüs, L.; Balajthy, Z. Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. Blood 2010, 116, 3933-3943.
19. Chhabra, A.; Verma, A; Mehta, K. Tissue transglutaminase promotes or suppresses tumors depending on cell context. Anticancer Res. 2009, 29, 1909-1919.
20. Siegel, M.; Strnad, P.; Watts, R.E.; Choi, K.; Jabri, B.; Omary, M.B.; Khosla, C. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One 2008, 3, e1861.
21. Lee, J.; Kim, Y.S.; Choi, D.H.; Bang, M.S.; Han, T.R.; Joh, T.H.; Kim, S.Y. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 2004, 279, 53725-53735.
22. Kim, D.S.; Park, S.S.; Nam, B.H.; Kim, I.H.; Kim, S.Y. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 2006, 66, 10936-10943.
23. Fésüs, L.; Szondy, Z. Transglutaminase 2 in the balance of cell death and survival. FEBS Lett. 2005, 579, 3297-3302.
24. Arends, M.J.; Wyllie, A.H. Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol. 1991, 32, 223-254.
25. Aggarwal, B.B.; Gehlot, P. Inflammation and cancer: How friendly is the relationship for cancer patients? Curr. Opin. Pharmacol. 2009, 9, 351-369.
26. Verderio, E.A.M.; Johnson, T.S.; Griffin, M. Transglutaminases in wound healing and inflammation. In Transglutaminases Family of Enzymes with Diverse Functions; Mehta, K., Eckert, R., Eds.; Karger A.G.: Basel, Switzerland, 2005; pp. 89-114.
27. Verderio, E.A.M.; Johnson, T.; Griffin, M. Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids 2004, 26, 387-404.
28. Kim, S.Y. Transglutaminase 2 in inflammation. Front. Biosci. 2006, 11, 3026-3035.
29. Quan, G.; Choi, J.Y.; Lee, D.S.; Lee, S.C. TGF-beta1 upregulates transglutaminase 2 and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch. Dermatol. Res. 2005, 297, 84-90.
30. Kuncio, G.S.; Tsyganskaya, M.; Zhu, J.; Liu, S-L.; Nagy, L.; Thomazy, V., Davies, P.J.; Zern, M.A. TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells. Am. J. Physiol. 1998, 274, G240-G245.
31. Mann, A.P.; Verma, A.; Sethi, G.; Manavathi, B., Wang, H.; Fok, J.Y.; Kunnumakkara, A.B.; Kumar, R.; Aggarwal, B.B.; Mehta, K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-{kappa} B in cancer cells: Delineation of a novel pathway. Cancer Res. 2006, 66, 8788-8795.
32. Johnson, K.; Hashimoto, S.; Lotz, M.; Pritzker, K.; Terkeltaub, R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am. J. Pathol. 2001, 159, 149-163.
33. Suto, N.; Ikura, K.; Sasaki, R. Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells. J. Biol. Chem. 1993, 268, 7469-7473.
34. Ajani, G.; Sato, N.; Mack, J.A.; Maytin, E.V. Cellular responses to disruption of the permeability barrier in a three-dimensional organotypic epidermal model. Exp. Cell. Res. 2007, 313, 3005-3015.
35. Falasca, L.; Farrace, M.G.; Rinaldi, A.; Tuosto, L.; Melino, G.; Piacentini, M. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J. Immunol. 2008, 180, 2616-2624.
36. Tatsukawa, H.; Fukaya, Y.; Frampton, G.; Martinez-Fuentes, A.; Suzuki, K.; Kuo, T.F.; Nagatsuma, K.; Shimokado, K.; Okuno, M.; Wu, J.; Iismaa, S.; Matsuura, T.; Tsukamoto, H.; Zern, M.A.; Graham, R.M.; Kojima, S. Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 2009, 136, 1783-1795.
37. Kim, D.S.; Kim, B.; Tahk, H.; Kim, D.H.; Ahn, E.R.; Choi, C.; Jeon, Y.; Park, S.Y.; Lee, H.; Oh, S.H.; Kim, S.Y. Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-κB activation. Biochem. Biophys. Res. Commun. 2010, 403, 479-484.
38. Seiving, B.; Ohlsson, K.; Linder, C.; Stenberg, P. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. Eur. J. Haematol. 1991, 46, 263-271.
39. Kojima, S.; Nara, K.; Rifkin, D.B. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J. Cell Biol. 1993, 121, 439-448.
40. Hsu, T.C.; Huang, C.Y.; Chiang, S.Y.; Lai, W.X.; Tsai, C.H.; Tzang, B.S. Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice. Eur. J. Pharmacol. 2008, 579, 382-389.
41. Akar, U.; Ozpolat, B.; Mehta, K.; Fok, J.; Kondo, Y.; Lopez-Berestein, G. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol. Cancer Res. 2007, 5, 241-249.
42. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to Virchow? Lancet 2001, 357, 539-545.
43. Thiery, P.J.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-887.
44. López-Novoa, J.M.; Nieto, M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 2009, 1, 303-314.
45. Jeanes, A.; Gottardi, C.J.; Yap, A.S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008, 27, 6920-6929.
46. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29, 4741-4751.
47. Wendt, M.K.; Allington, T.M.; Schiemann, W.P. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009, 5, 1145-1168.
48. Kumar, A.; Xu, J.; Brady, S.; Gao, H.; Yu, D.; Reuben, J.; Mehta, K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5, e13390.
49. Verma, A.; Guha, S.; Wang, H; Fok, J.Y.; Koul, D.; Abbruzzese, J.; Mehta, K. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin. Cancer Res. 2008, 14, 1997-2005.
50. Verma, A.; Guha, S.; Diagaradjane, P.; Kunnumakkara, A.B.; Sanguino, A.M.; Lopez-Berestein, G.; Sood, A.K.; Aggarwal, B.B.; Krishnan, S.; Gelovani, J.G.; Mehta, K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin. Cancer Res. 2008, 14, 2476-2483.
51. Hwang, J.Y.; Mangala, L.S.; Fok, J.Y.; Lin, Y.G.; Merritt, W.M.; Spannuth, W.A.; Nick, A.M.; Fiterman, D.J.; Vivas-Mejia, P.E.; Deavers, M.T.; et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008, 68, 5849-5858.
52. Frese-Schaper, M.; Schardt, J.A.; Sakai, T.; Carboni, G.L.; Schmid, R.A.; Frese, S. Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett. 2010, 584, 2867-2871.
53. Fok, J.Y.; Ekmekcioglu, S.; Mehta, K. Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther. 2006, 5, 1493-1503.
54. Yuan, L., Choi, K.; Khosla, C.; Zheng, X.; Higashikubo, R.; Chicoine, M.R.; Rich, K.M. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol. Cancer Ther. 2005, 4, 1293-1302.
55. Wang, Z.; Li, Y.; Ahmad, A.; Banerjee, S.; Azmi, A.S.; Kong, D. Sarkar, F.H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroentrol. Hepatol. 2011, 8, 27-33.
56. Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820-5828.
57. Li, Y.; Kong, D.; Wang, Z.; Ali, S.; Philip, P.A.; Sarkar, F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabineresistant pancreatic cancer cells. Cancer Res. 2009, 69, 6704-6712.
58. Shao, M.; Cao, L.; Shen, C.; Satpathy, M.; Chelladurai, B.; Bigsby, R.M.; Nakshatri, H.; Matei, D. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 2009, 69, 9192-9201.
59. Yao, J.; Cai, H.H.; Wei, J.S.; An, Y.; Ji, Z.L.; Lu, Z.P.; Wu, J.L.; Chen, P.; Jiang, K.R.; Dai, C.C.; Qian, Z.Y.; Xu, Z.K.; Miao, Y. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol. Rep. 2010, 23, 1375-1382.
60. Mimeault, M.; Johansson, S.L.; Senapati, S.; Momi, N.; Chakraborty, S.; Batra, S.K. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 2010, 295, 69-84.
61. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
62. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2, 301-310.
63. Orlowski, R.Z.; Baldwin, Jr., A.S. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 2002, 8, 385-389.
64. Margit, D.; Huber, A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114, 5669-5681.
65. Wu, Y.; Deng, J.; Rychahou, P.G.; Qui, S.; Evers, B.M.; Zhou, B.P. Stabilization of Sanil by NF-κB is required for inflammation-induced cell migration and invasion. Cell 2009, 15, 416-428.
66. Chua, H.L.; Bhat-Nakshatri, P.; Clare, S.E.; Morimiya, A.; Badve, S.; Nakshatari, H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007, 26, 711-724.
67. Kim, Y.; Eom, S.; Kim, K.; Lee, Y.S.; Choe, J.; Hahn, J.H.; Lee, H.; Kim, Y.M.; Ha, K.S.; Ro, J.Y.; Jeoung, D. Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation. Mol. Immunol. 2010, 47, 1010-1022.
68. Landen, C.N., Jr.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-Berestein, G.; Sood, A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65, 6910-6918.
69. Halder, J.; Kamat, A.A.; Landen, C.N., Jr.; Han, L.Y.; Lutgendorf, S.K.; Lin, Y.G.; Merritt, W.M.; Jennings, N.B.; Chavez-Reyes, A.; Coleman, R.L.; et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 2006, 12, 4916-4924.